Product Description
A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called taxanes.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00044525 |
NCT00044525 | P2 |
Completed |
Breast Cancer |
2004-02-01 |
2019-03-21 |
Treatments |
|
NCT00044538 |
NCT00044538 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00044551 |
NCT00044551 | P2 |
Completed |
Lymphoma, Non-Hodgkin |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|